Literature DB >> 19023513

Glucose homeostasis abnormalities in cardiac intensive care unit patients.

Jacob Ilany1, Ibrahim Marai, Ohad Cohen, Shlomi Matetzky, Malka Gorfine, Idit Erez, Hanoch Hod, Avraham Karasik.   

Abstract

The aim of this study was to characterize the abnormalities in glucose homeostasis in intensive care unit patients following an acute coronary event. The study population included all non-diabetic patients ages 20-80 years that were admitted to a coronary intensive unit. Glucose, insulin and C-peptide levels during an oral glucose tolerance test (OGTT) were measured during the acute admission. From January to September 2003, 277 patients were admitted to the coronary unit. Of these, 127 patients underwent an OGTT. Of these, only 29 patients (23%) exhibited normal glucose metabolism. The remainder had type 2 diabetes (32%), impaired glucose tolerance (37%) or isolated impaired fasting glucose (8%, 100-125 mg/dl). Based on homeostasis model assessment (HOMA) calculations, diabetic patients had impaired beta-cell function and patients with elevated fasting glucose levels were insulin resistant. Beta-cell dysfunction during the acute stress seems to contribute to the glucose abnormalities. Most patients who experience an acute coronary event demonstrate abnormal glucose metabolism. Post glucose-load abnormalities are more common than abnormal fasting glucose level in this situation. It is postulated that the acute stress of a coronary event may contribute to the dysglycemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19023513     DOI: 10.1007/s00592-008-0077-0

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  1 in total

1.  Admission glucose, fasting glucose, HbA1c levels and the SYNTAX score in non-diabetic patients undergoing coronary angiography.

Authors:  Yaron Arbel; Margalit Zlotnik; Amir Halkin; Ofer Havakuk; Shlomo Berliner; Itzhak Herz; Itay Rabinovich; Gad Keren; Shmuel Bazan; Ariel Finkelstein; Shmuel Banai
Journal:  Clin Res Cardiol       Date:  2013-11-24       Impact factor: 5.460

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.